Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Id2 Collaborates with Id3 To Suppress Invariant NKT and Innate-like Tumors.

Li J, Roy S, Kim YM, Li S, Zhang B, Love C, Reddy A, Rajagopalan D, Dave S, Diehl AM, Zhuang Y.

J Immunol. 2017 Apr 15;198(8):3136-3148. doi: 10.4049/jimmunol.1601935. Epub 2017 Mar 3.

PMID:
28258199
2.

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.

Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Nathan M, Wotherspoon A, Gao ZH, Shi Y, Van den Eynden G, Daley F, Peckitt C, Tan X, Salman A, Lazaris A, Gazinska P, Berg TJ, Eltahir Z, Ritsma L, Van Rheenen J, Khashper A, Brown G, Nystrom H, Sund M, Van Laere S, Loyer E, Dirix L, Cunningham D, Metrakos P, Reynolds AR.

Nat Med. 2016 Nov;22(11):1294-1302. doi: 10.1038/nm.4197. Epub 2016 Oct 17.

3.

The Wnt/β-catenin signaling/Id2 cascade mediates the effects of hypoxia on the hierarchy of colorectal-cancer stem cells.

Dong HJ, Jang GB, Lee HY, Park SR, Kim JY, Nam JS, Hong IS.

Sci Rep. 2016 Mar 11;6:22966. doi: 10.1038/srep22966.

4.

Id2 deletion attenuates Apc-deficient ileal tumor formation.

Biyajima K, Kakizaki F, Shen X, Mori K, Sugai M, Taketo MM, Yokota Y.

Biol Open. 2015 Jul 10;4(8):993-1001. doi: 10.1242/bio.012252.

5.
6.

Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines.

Langenfeld E, Hong CC, Lanke G, Langenfeld J.

PLoS One. 2013 Apr 12;8(4):e61256. doi: 10.1371/journal.pone.0061256. Print 2013.

7.

A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.

Weiswald LB, Richon S, Massonnet G, Guinebretière JM, Vacher S, Laurendeau I, Cottu P, Marangoni E, Nemati F, Validire P, Bellet D, Bièche I, Dangles-Marie V.

Br J Cancer. 2013 Apr 30;108(8):1720-31. doi: 10.1038/bjc.2013.132. Epub 2013 Mar 28.

8.

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.

Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2010 Dec;9(12):3186-99. doi: 10.1158/1535-7163.MCT-10-0563. Epub 2010 Oct 1.

9.

Negative energy balance and hepatic gene expression patterns in high-yielding dairy cows during the early postpartum period: a global approach.

McCarthy SD, Waters SM, Kenny DA, Diskin MG, Fitzpatrick R, Patton J, Wathes DC, Morris DG.

Physiol Genomics. 2010 Nov 15;42A(3):188-99. doi: 10.1152/physiolgenomics.00118.2010. Epub 2010 Aug 17.

10.

A distinct spectrum of copy number aberrations in pediatric high-grade gliomas.

Bax DA, Mackay A, Little SE, Carvalho D, Viana-Pereira M, Tamber N, Grigoriadis AE, Ashworth A, Reis RM, Ellison DW, Al-Sarraj S, Hargrave D, Jones C.

Clin Cancer Res. 2010 Jul 1;16(13):3368-77. doi: 10.1158/1078-0432.CCR-10-0438. Epub 2010 Jun 22.

11.

Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines.

Nagel S, Venturini L, Marquez VE, Meyer C, Kaufmann M, Scherr M, MacLeod RA, Drexler HG.

Mol Cancer. 2010 Jun 17;9:151. doi: 10.1186/1476-4598-9-151.

12.

A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets.

Grade M, Hummon AB, Camps J, Emons G, Spitzner M, Gaedcke J, Hoermann P, Ebner R, Becker H, Difilippantonio MJ, Ghadimi BM, Beissbarth T, Caplen NJ, Ried T.

Int J Cancer. 2011 Mar 1;128(5):1069-79. doi: 10.1002/ijc.25453.

13.

Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F.

Coma S, Amin DN, Shimizu A, Lasorella A, Iavarone A, Klagsbrun M.

Cancer Res. 2010 May 1;70(9):3823-32. doi: 10.1158/0008-5472.CAN-09-3048. Epub 2010 Apr 13.

14.

Lipidic systems for in vivo siRNA delivery.

Wu SY, McMillan NA.

AAPS J. 2009 Dec;11(4):639-52. doi: 10.1208/s12248-009-9140-1. Epub 2009 Sep 9. Review.

Supplemental Content

Support Center